Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sims

Showing results (491-500 of 528) with videos related to

Pageof 53
Sort By:
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|March 30, 2011
DISC1 exon 11 rare variants found more commonly in schizoaffective spectrum cases than controlsE K Green, D Grozeva, R Sims, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
The Journal of Prevention of Alzheimer'S Disease|June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task ForceD Angioni, O Hansson, R J Bateman, et al.
The Journal of Prevention of Alzheimer'S Disease|September 29, 2021
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 ImagingS L Lowe, C Duggan Evans, S Shcherbinin, et al.
The Review of Scientific Instruments|November 7, 2012
Gamma-to-electron magnetic spectrometer (GEMS): an energy-resolved γ-ray diagnostic for the National Ignition FacilityY Kim, H W Herrmann, T J Hilsabeck, et al.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Journal of Neurochemistry|July 1, 1983
Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's diseaseD M Bowen, S J Allen, J S Benton, et al.
Physical Review Letters|October 13, 2007
Fermi surface of CeIn3 above the Néel critical fieldN Harrison, S E Sebastian, C H Mielke, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN StudiesR A Sperling, M C Donohue, R A Rissman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.
Pageof 53

Showing results (491-500 of 528) with videos related to

Sort By:
Pageof 53
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|March 30, 2011
DISC1 exon 11 rare variants found more commonly in schizoaffective spectrum cases than controlsE K Green, D Grozeva, R Sims, et al.
Nature Communications|April 5, 2020
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's diseaseShorena Janelidze, Erik Stomrud, Ruben Smith, et al.
The Journal of Prevention of Alzheimer'S Disease|June 25, 2023
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task ForceD Angioni, O Hansson, R J Bateman, et al.
The Journal of Prevention of Alzheimer'S Disease|September 29, 2021
Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 ImagingS L Lowe, C Duggan Evans, S Shcherbinin, et al.
The Review of Scientific Instruments|November 7, 2012
Gamma-to-electron magnetic spectrometer (GEMS): an energy-resolved γ-ray diagnostic for the National Ignition FacilityY Kim, H W Herrmann, T J Hilsabeck, et al.
The New England Journal of Medicine|July 17, 2023
Trial of Solanezumab in Preclinical Alzheimer's DiseaseReisa A Sperling, Michael C Donohue, Rema Raman, et al.
Journal of Neurochemistry|July 1, 1983
Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's diseaseD M Bowen, S J Allen, J S Benton, et al.
Physical Review Letters|October 13, 2007
Fermi surface of CeIn3 above the Néel critical fieldN Harrison, S E Sebastian, C H Mielke, et al.
The Journal of Prevention of Alzheimer'S Disease|July 24, 2024
Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN StudiesR A Sperling, M C Donohue, R A Rissman, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 10, 2026
Infusion-related reactions in donanemab-treated participants with early symptomatic Alzheimer's diseasePaul Ardayfio, Garrett R Mullins, Rashna Khanna, et al.
Pageof 53